相似文献
1
Critical evaluation of urinary markers for bladder cancer detection and monitoring.
Rev Urol. 2008 Spring;10(2):120-35.
2
Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects.
Biomark Med. 2008 Apr;2(2):165-80. doi: 10.2217/17520363.2.2.165.
3
Current bladder cancer tests: unnecessary or beneficial?
Crit Rev Oncol Hematol. 2003 Aug;47(2):91-107. doi: 10.1016/s1040-8428(03)00074-x.
4
Current bladder tumor tests: does their projected utility fulfill clinical necessity?
J Urol. 2001 Apr;165(4):1067-77.
5
Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Urol Oncol. 2016 Oct;34(10):460-8. doi: 10.1016/j.urolonc.2016.05.028. Epub 2016 Jun 29.
6
Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Int J Med Sci. 2017 Jul 19;14(9):811-819. doi: 10.7150/ijms.19929. eCollection 2017.
7
Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Ann Chir Gynaecol. 2001;90(4):261-5.
8
[Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Arch Esp Urol. 2002 Jan-Feb;55(1):41-9.
9
Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
Eur Urol. 2019 May;75(5):853-860. doi: 10.1016/j.eururo.2018.11.055. Epub 2018 Dec 12.
10
Alternatives to cytology in the management of non-muscle invasive bladder cancer.
Curr Treat Options Oncol. 2004 Oct;5(5):377-89. doi: 10.1007/s11864-004-0028-0.
引用本文的文献
1
From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer.
Curr Oncol Rep. 2024 Aug;26(8):945-958. doi: 10.1007/s11912-024-01555-0. Epub 2024 Jun 5.
2
Clinical Validation of the Proenkephalin () Methylation Urine Test for Monitoring Recurrence of Non-muscle-invasive Bladder Cancer.
Eur Urol Open Sci. 2024 Mar 7;62:99-106. doi: 10.1016/j.euros.2024.02.010. eCollection 2024 Apr.
3
Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis.
Front Oncol. 2024 Feb 27;14:1303918. doi: 10.3389/fonc.2024.1303918. eCollection 2024.
4
Hypermethylation Loci of ZNF671, IRF8, and OTX1 as Potential Urine-Based Predictive Biomarkers for Bladder Cancer.
Diagnostics (Basel). 2024 Feb 21;14(5):468. doi: 10.3390/diagnostics14050468.
5
Identification and validation of prognostic signature genes of bladder cancer by integrating methylation and transcriptomic analysis.
Sci Rep. 2024 Jan 3;14(1):368. doi: 10.1038/s41598-023-50740-x.
6
Bladder Cancer and Artificial Intelligence: Emerging Applications.
Urol Clin North Am. 2024 Feb;51(1):63-75. doi: 10.1016/j.ucl.2023.07.002. Epub 2023 Aug 25.
7
Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers.
Int J Mol Sci. 2023 Sep 21;24(18):14374. doi: 10.3390/ijms241814374.
8
Urine biomarkers in bladder cancer - current status and future perspectives.
Nat Rev Urol. 2023 Oct;20(10):597-614. doi: 10.1038/s41585-023-00773-8. Epub 2023 May 24.
9
Exploring solid-phase proximity ligation assay for survivin detection in urine.
PLoS One. 2022 Jun 29;17(6):e0270535. doi: 10.1371/journal.pone.0270535. eCollection 2022.
10
Characterization of the Peri-Membrane Fluorescence Phenomenon Allowing the Detection of Urothelial Tumor Cells in Urine.
Cancers (Basel). 2022 Apr 26;14(9):2171. doi: 10.3390/cancers14092171.
本文引用的文献
1
Cancer statistics, 2007.
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. doi: 10.3322/canjclin.57.1.43.
2
UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.
Eur Urol. 2007 May;51(5):1275-80; discussion 1280. doi: 10.1016/j.eururo.2006.10.044. Epub 2006 Oct 30.
3
Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
J Urol. 2006 Sep;176(3):919-26; discussion 926. doi: 10.1016/j.juro.2006.04.017.
4
Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.
Cancer. 2006 Sep 1;107(5):982-90. doi: 10.1002/cncr.22084.
5
Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis.
Urol Oncol. 2006 Jul-Aug;24(4):338-43. doi: 10.1016/j.urolonc.2005.11.025.
6
Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder.
BJU Int. 2006 May;97(5):997-1001. doi: 10.1111/j.1464-410X.2006.06036.x. Epub 2006 Mar 17.
7
Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Cancer. 2006 Apr 15;106(8):1701-7. doi: 10.1002/cncr.21795.
8
Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.
JAMA. 2006 Jan 18;295(3):299-305. doi: 10.1001/jama.295.3.299.
9
Highly specific urine-based marker of bladder cancer.
Urology. 2005 Dec;66(6):1256-60. doi: 10.1016/j.urology.2005.07.010.
10
Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology.
Cancer Res. 2005 Aug 15;65(16):7145-50. doi: 10.1158/0008-5472.CAN-05-1142.
Zotero 插件